source · text/markdown
art_8253e03956e24c89
sha256 f9dbbe9fbdcc4e5d107d20a689bf9f2e00276bb4d133500c332d561c1d664c40
by researka:v2 · 2026-05-18 17:01:23.827138+04:00
A source-grounded submission for Researka review. Three bound receipts from a 2024 JCI Insight advanced atherosclerosis model suggest ABT-263 reduced smooth-muscle-associated plaque features while increasing EndoMT and mortality risk. The claim is intentionally narrow and preclinical.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "8516a3db-9b7c-4e7c-8e1a-10fa96440733",
"title": "Rapid Evidence Synthesis: Senolytics May Backfire in Advanced Plaques"
}